<DOC>
	<DOCNO>NCT01380262</DOCNO>
	<brief_summary>Up 60 % patient metastatic colorectal cancer treat one monoclonal antibody target epidermal growth factor receptor ( EGFR ) . This treatment associate specific spectrum toxicity : acne-like rash limit erythema , often severe pruritus , sometimes combine type skin toxicity ( hair nail change ) . Previously STEPP study investigator show pre-emptive treatment oral doxycycline ( 200 mg daily ) , topical steroid sun blocker reduce number severe skin side effect panitumumab . The study design describe profile skin toxicity EGFR block drug combine low-dose doxycycline ( 100 mg daily ) use pre-emptive manner .</brief_summary>
	<brief_title>Pre-emptive Low-dose Doxycycline During Anti-EGFR Treatment</brief_title>
	<detailed_description>Patients metastatic colorectal cancer treat cetuximab panitumumab usually develop skin toxicity impair patient ' quality life well limit treatment . We design trial ass effect simplify protocol pre-emptive treatment observe skin toxicity cetuximab panitumumab treatment colorectal cancer . The study cohort observational , single center study result estimation particular type toxicity , especially occurence severe ( grade 2 3 ) side effect assess tolerance doxycyline prolong administration . The observation study biweekly continue 8 week .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>diagnosis metastatic colorectal cancer , previously qualify either cetuximab panitumumab , write consent . previous administration cetuximab panitumumab , contradiction receive oral doxycycline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Skin Rash</keyword>
	<keyword>Pre-emptive treatment</keyword>
	<keyword>Doxycycline</keyword>
	<keyword>Anti-EGFR antibody</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Panitumumab</keyword>
</DOC>